Literature DB >> 9427689

The therapeutic potential of ribozymes.

H A James1, I Gibson.   

Abstract

Ribozymes are catalytic RNA molecules that recognize their target RNA in a highly sequence-specific manner. They can therefore be used to inhibit deleterious gene expression (by cleavage of the target mRNA) or even repair mutant cellular RNAs. Targets such as the mRNAs of oncogenes (resulting from base mutations or chromosome translocations, eg, ras or bcr-abl) and viral genomes and transcripts (human immunodeficiency virus-type 1 [HIV-1]) are ideal targets for such sequence-specific agents. The aim of this review is therefore to introduce the different classes of ribozymes, highlighting some of the chemistry of the reactions they catalyze, to address the specific inhibition of genes by ribozymes, the problems yet to be resolved, and how new developments in the field give hope to the future for ribozymes in the therapeutic field.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427689

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Antisense cancer therapy: the state of the science.

Authors:  D M Kushner; R H Silverman
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Ophthalmology in the post-genomic era.

Authors:  G C Black; M E Boulton; P N Bishop; D McLeod
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

3.  HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.

Authors:  B Bramlage; E Luzi; F Eckstein
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

Review 4.  Small nucleolar RNAs: versatile trans-acting molecules of ancient evolutionary origin.

Authors:  Michael P Terns; Rebecca M Terns
Journal:  Gene Expr       Date:  2002

5.  A selection system for identifying accessible sites in target RNAs.

Authors:  W H Pan; H F Devlin; C Kelley; H C Isom; G A Clawson
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

6.  Substrate specificity and reaction kinetics of an X-motif ribozyme.

Authors:  Denis Lazarev; Izabela Puskarz; Ronald R Breaker
Journal:  RNA       Date:  2003-06       Impact factor: 4.942

7.  Inorganic nanovectors for nucleic acid delivery.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Anisha A D'Souza; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

8.  Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation.

Authors:  M Krüger; C Beger; P J Welch; J R Barber; M P Manns; F Wong-Staal
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 9.  Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor.

Authors:  Sijin Guo; Xijun Piao; Hui Li; Peixuan Guo
Journal:  Methods       Date:  2018-03-09       Impact factor: 3.608

10.  Ribozyme-mediated REV1 inhibition reduces the frequency of UV-induced mutations in the human HPRT gene.

Authors:  Denise R Clark; Wolfgang Zacharias; Luminita Panaitescu; W Glenn McGregor
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.